KR20250009977A - 암 치료를 위한 알로스테릭 및 오르토스테릭 egfr 억제제의 조합물 - Google Patents
암 치료를 위한 알로스테릭 및 오르토스테릭 egfr 억제제의 조합물 Download PDFInfo
- Publication number
- KR20250009977A KR20250009977A KR1020247037653A KR20247037653A KR20250009977A KR 20250009977 A KR20250009977 A KR 20250009977A KR 1020247037653 A KR1020247037653 A KR 1020247037653A KR 20247037653 A KR20247037653 A KR 20247037653A KR 20250009977 A KR20250009977 A KR 20250009977A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- combination
- indazol
- mmol
- egfr inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22173211 | 2022-05-13 | ||
| EP22173211.8 | 2022-05-13 | ||
| EP22175302 | 2022-05-25 | ||
| EP22175302.3 | 2022-05-25 | ||
| PCT/EP2023/062530 WO2023217924A1 (en) | 2022-05-13 | 2023-05-11 | Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250009977A true KR20250009977A (ko) | 2025-01-20 |
Family
ID=86558741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247037653A Pending KR20250009977A (ko) | 2022-05-13 | 2023-05-11 | 암 치료를 위한 알로스테릭 및 오르토스테릭 egfr 억제제의 조합물 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20260007678A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4522113A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025516543A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250009977A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119173253A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023268579A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3255503A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202408534A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023217924A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2961187T3 (es) | 2019-06-21 | 2024-03-08 | Hoffmann La Roche | Inhibidor de EGFR para el tratamiento del cáncer |
| CN116507328A (zh) | 2020-12-01 | 2023-07-28 | 豪夫迈·罗氏有限公司 | 新的吲唑衍生物 |
| IL303064A (en) | 2020-12-01 | 2023-07-01 | Hoffmann La Roche | NEW INDAZOLE ACETYLENE DERIVATIVES |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2961187T3 (es) * | 2019-06-21 | 2024-03-08 | Hoffmann La Roche | Inhibidor de EGFR para el tratamiento del cáncer |
| CN116507328A (zh) * | 2020-12-01 | 2023-07-28 | 豪夫迈·罗氏有限公司 | 新的吲唑衍生物 |
| IL303064A (en) * | 2020-12-01 | 2023-07-01 | Hoffmann La Roche | NEW INDAZOLE ACETYLENE DERIVATIVES |
| JP7798887B2 (ja) * | 2020-12-01 | 2026-01-14 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規インダゾール誘導体 |
-
2023
- 2023-05-11 EP EP23726084.9A patent/EP4522113A1/en active Pending
- 2023-05-11 AU AU2023268579A patent/AU2023268579A1/en active Pending
- 2023-05-11 WO PCT/EP2023/062530 patent/WO2023217924A1/en not_active Ceased
- 2023-05-11 CN CN202380039827.0A patent/CN119173253A/zh active Pending
- 2023-05-11 KR KR1020247037653A patent/KR20250009977A/ko active Pending
- 2023-05-11 JP JP2024566197A patent/JP2025516543A/ja active Pending
- 2023-05-11 CA CA3255503A patent/CA3255503A1/en active Pending
- 2023-05-11 US US18/865,274 patent/US20260007678A1/en active Pending
- 2023-05-12 TW TW112117726A patent/TW202408534A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3255503A1 (en) | 2023-11-16 |
| US20260007678A1 (en) | 2026-01-08 |
| CN119173253A (zh) | 2024-12-20 |
| EP4522113A1 (en) | 2025-03-19 |
| JP2025516543A (ja) | 2025-05-30 |
| TW202408534A (zh) | 2024-03-01 |
| WO2023217924A1 (en) | 2023-11-16 |
| AU2023268579A1 (en) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7530391B2 (ja) | がんの治療のためのｅｇｆｒ阻害剤 | |
| EP3986566B1 (en) | New egfr inhibitors | |
| EP3735299B1 (en) | Fused ring compounds | |
| US20220281893A1 (en) | Tetracyclic oxazepine compounds and uses thereof | |
| JP2025516543A (ja) | がんの治療のためのアロステリックおよびオルソステリックｅｇｆｒ阻害剤の組み合わせ | |
| JP2020502246A (ja) | ２−ベンゾピラジニル−ｎ−ヘテロアリール−２−フェニル−アセトアミド化合物 | |
| JP7701360B2 (ja) | Ｅｇｆｒ阻害剤 | |
| JP5464609B2 (ja) | チューブリン重合阻害剤としてのキナゾリノン誘導体 | |
| KR20250012058A (ko) | 신규 이미다졸 유도체 | |
| KR20230116799A (ko) | 신규 이미다졸 아세틸렌 유도체 | |
| TW202342461A (zh) | 雜環化合物及使用方法 | |
| HK40115468A (en) | Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer | |
| HK40071776A (en) | Egfr inhibitors | |
| HK40063822A (en) | Egfr inhibitor for the treatment of cancer | |
| WO2025152908A1 (zh) | 氨基杂芳基大环化合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |